0.00
100.00%
-58.70
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché MRTX Giù?
Forum
Previsione
Frazionamento azionario
Mirati Therapeutics Inc Borsa (MRTX) Ultime notizie
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion - MSN
MSN
Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing - MSN
MSN
Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo New Zealand News
Yahoo New Zealand News
Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago - Yahoo Canada Shine On
Yahoo Canada Shine On
Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo New Zealand News
Yahoo New Zealand News
Even after rising 4.0% this past week, Mirati Therapeutics (NASDAQ:MRTX) shareholders are still down 76% over the ... - Yahoo Canada Shine On
Yahoo Canada Shine On
What You Need To Know About The Mirati Therapeutics, Inc. (NASDAQ:MRTX) Analyst Downgrade Today - Yahoo Movies UK
Yahoo Movies UK
Citi upgrades Mirati to buy; cites valuation, leadership change - MSN
MSN
TOLREMO Welcomes Dr. Alan Sandler to Scientific Advisory Board - Yahoo Canada Finance
Yahoo Canada Finance
Broader KRAS inhibition methods include chaperoning, gluing, vaccinating - BioWorld Online
BioWorld Online
Merck puts KRAS cancer drug competitor to the test - Yahoo Finance
Yahoo Finance
Bristol Myers Squibb to lay off hundreds of workers following its $4.8B merger with this San Diego biotech - The San Diego Union-Tribune
The San Diego Union-Tribune
Bristol Myers says KRAS drug succeeds in key trial - Yahoo Finance
Yahoo Finance
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and ... - Business Wire
Business Wire
Bristol Myers Squibb's Abecma recommended for EU approval - Pharmaceutical Technology
Pharmaceutical Technology
Billionaire Joe Lewis Nets 730% Gain on Stock Behind US Charges - Bloomberg
Bloomberg
Tango Therapeutics: Making Its Way Into Clinic With 4 Cancer Drugs (NASDAQ:TNGX) - Seeking Alpha
Seeking Alpha
Bristol Myers Squibb concludes Mirati acquisition for $5.8bn - Pharmaceutical Technology
Pharmaceutical Technology
Bristol Myers Squibb completes acquisition of Mirati Therapeutics, strengthening oncology portfolio - ROI-NJ.com
ROI-NJ.com
2023's top 10 clinical trial flops - Fierce Biotech
Fierce Biotech
Mirati Therapeutics stock ticks higher amid Nasdaq delisting for sale to Bristol-Myers - Seeking Alpha
Seeking Alpha
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
Zacks Investment Research
European Commission Approves Adagrasib in KRAS G12C-Mutated NSCLC - Cancer Network
Cancer Network
Jan. 10 Quick Takes: Coherus ends TIGIT deal with Junshi - BioCentury
BioCentury
HDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the ... - GlobeNewswire
GlobeNewswire
Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation
Zacks Investment Research
Mirati Therapeutics describes new GTPase KRAS and mutant inhibitors for cancer - BioWorld Online
BioWorld Online
Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
Seeking Alpha
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
Zacks Investment Research
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
Zacks Investment Research
Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push - CNBC
CNBC
Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition (NASDAQ:MRTX) - Seeking Alpha
Seeking Alpha
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
Zacks Investment Research
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B - Yahoo Finance
Yahoo Finance
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024 - Yahoo Finance
Yahoo Finance
EnerSys To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
Analyst Expectations For Mirati Therapeutics's Future
Benzinga
Sanofi licenses fourth NK cell engager from Innate Pharma - Pharmaceutical Technology
Pharmaceutical Technology
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Zacks Investment Research
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
Zacks Investment Research
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug - Yahoo Finance
Yahoo Finance
Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?
Zacks Investment Research
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032) | DelveInsight - PR Newswire
PR Newswire
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Zacks Investment Research
MRTX-1257 enhances radiotherapy effect in preclinical setting - BioWorld Online
BioWorld Online
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for ... - PR Newswire
PR Newswire
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations - Yahoo Finance
Yahoo Finance
Mirati wins conditional UK approval for Krazati in NSCLC - Pharmaceutical Technology
Pharmaceutical Technology
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for ... - PR Newswire
PR Newswire
Capitalizzazione:
|
Volume (24 ore):